Group 6B: HR+ Breast Cancer; Hormone Therapy; Novel Targets & Treatments



Thursday, Dec 15 6:00 pm – 7:30 pm Eastern Time (US/New York)



Poster #OT2-01-02

The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors

Poster #P3-07-15:

Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

Mentor: Kelly Shanahan, M.D.

In 2008, Kelly Shanahan had everything going for her: a busy and successful ob-gyn practice; a precocious 9-year- old daughter; and a well used passport from traveling all over the world with her family to attend conferences, with a liberal dose of vacation on the side. When she was diagnosed with stage IIB breast cancer in April, she considered it a mere bump in the road.

And for five years, breast cancer was an aside, something to put in the past medical history section of forms. Even when she developed sudden back pain, Kelly never thought it could be breast cancer rearing its ugly head – a pulled muscle, a herniated disc maybe, but not what it turned out to be: metastatic breast cancer in virtually every bone in her body, with a fractured vertebrae and an about to break left femur. Kelly was diagnosed on her 53rd birthday.

Neuropathy from the chemo did cost her her career, but she has found a new purpose in advocacy. Kelly is on the board of METAvivor, a member of the Metastatic Breast Cancer Alliance, a Komen Advocate in Science, a grant reviewer, and research advocate. Kelly Shanahan is a mother, a wife, a daughter, a doctor, a woman LIVING with metastatic breast cancer.

Twitter: @stage4Kelly

Scientist: Nicole Traphagen, Ph.D.

I’m from upstate New York. My research interests are focused on hormone receptor biology and endocrine resistance in cancer, and in developing treatment strategies for endocrine resistant disease.  I received my PhD in Cancer Biology from Dartmouth College, where I worked under the supervision of Todd Miller to determine the anti-cancer mechanism of action of estrogen therapy in breast cancer.  I also have a B.S. in Biomolecular Science from Clarkson University. In my free time I enjoy reading, running, and hiking with my dog, and I love to travel and visit new places.

Twitter: @NicoleTraphagen